Search | Clinical Trials Finder

Conditions: Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
Interventions: ASP3772, PCV13, PPSV23; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 630 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 26
States / cities: Banning, California • San Diego, California • San Marcos, California + 21 more

Conditions: Pathogen Resistance, Pneumococcal Infection, Pneumonia
Interventions: Colistimethate sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Cleveland, Ohio

Conditions: HIV Infections
Interventions: Thalidomide; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, Ceftriaxone, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Impetigo, Secondarily Infected Traumatic Lesions
Interventions: TD1414 2% cream, Bactroban® (mupirocin) 2% cream; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 2 Years and older
Enrollment: 773 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Anniston, Alabama

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™, PNEUMOVAX™23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 652 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 15
States / cities: Chandler, Arizona • Phoenix, Arizona • Spring Valley, California + 12 more

Conditions: Pneumococcal Infection
Interventions: V116, Placebo, PCV15, PPSV23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 518 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Mesa, Arizona • Hialeah, Florida • West Palm Beach, Florida + 5 more

Conditions: Skin Infection, Bacterial Infection
Interventions: Daptomycin, Brilacidin; Drug
Lead sponsor: Cellceutix Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: Chula Vista, California • La Mesa, California • Oceanside, California + 1 more

Conditions: Pneumococcal Vaccines
Interventions: 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more

Conditions: Beta Haemolytic Streptococcal Infection
Interventions: GBS III-TT, Tetanus and diptheria toxoids vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Influenza, Infections, Pneumococcal
Interventions: Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call, Arm 5: IVR call; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Streptococcal Sore Throat
Interventions: Not listed
Lead sponsor: IQuum, Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Norwich, Connecticut • Savannah, Georgia • Rochester, New York + 2 more

Conditions: Pneumococcal Infections
Interventions: V114, QIV, Matching Placebo for V114; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 45
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 39 more

Conditions: Infections, Streptococcal, Streptococcal Infections
Interventions: GBS Vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 1,053 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Redding, California • Lenexa, Kansas • Baltimore, Maryland + 2 more

Conditions: Drug Use, Opioid-use Disorder
Interventions: Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment; Drug
Lead sponsor: Laura Fanucchi; Other
Eligibility: 18 Years to 99 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency
Interventions: Not listed
Lead sponsor: Richard Frye; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Infections, Streptococcal
Interventions: Pneumococcal vaccine GSK2189242A, Placebo, Prevnar 13®, PedvaxHIB®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 1,806 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Chinle, Arizona • Fort Defiance, Arizona • Whiteriver, Arizona + 2 more

Conditions: Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions: AFX3772, Prevnar 13, Prevnar 20; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 42 Days to 90 Days
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 42
States / cities: Jonesboro, Arkansas • Los Angeles, California • Miami, Florida + 35 more

Conditions: Pneumococcal Vaccines
Interventions: 31 valent pneumococcal conjugate vaccine, PCV20, PCV21; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,049 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 30
States / cities: Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more

Conditions: Pneumococcal Disease
Interventions: V116, Placebo, PCV15, PPSV23, PCV15 - Part B; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more

Conditions: Pneumonia
Interventions: PCV7, Prevnar®, Pneumovax 23; Biological
Lead sponsor: Kaiser Permanente; Other
Eligibility: 70 Years to 79 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Pneumococcal Infections
Interventions: PCV7 + PPV23, 2 months, PCV7 + PPV23, 6 months; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 55 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Anchorage, Alaska

Conditions: Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Interventions: 13-valent Pneumococcal Conjugate Vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 5 Years
Enrollment: 373 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Akiak, Alaska • Bethel, Alaska • Chefornak, Alaska + 18 more

Conditions: Pneumococcal Disease
Interventions: PG4, 20-valent pneumococcal conjugate vaccine (20vPnC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 42 Days to 98 Days
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Estero, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 14 more

Search by objective public record fields.

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

Aerosolized and Intravenous Colistin in Healthy Adults

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Prevention of GBS Colonization Via Immunity

System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts

In Vitro Diagnostic Device for the Detection of Strep A

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine

Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

Patterns of Neurodevelopmental Disorders

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

Pneumococcal Adult-dose Ranging Immunization Study

Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants